Imaging damaged lung tissue
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find use, for example, in detecting and treating a pulmonary condition such as emphysema.
1 . A method of imaging damaged lung tissue, comprising:
administering to a subject in need thereof a composition comprising an imaging moiety and a targeting moiety wherein said moieties are coupled and wherein said targeting moiety targets damaged lung tissue; and
imaging said damaged lung tissue.
2 . The method as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid.
3 . The method as recited in claim 1 wherein said composition does not comprise a polysaccharide or a carbohydrate moiety.
4 . The method as recited in claim 1 wherein said composition does not comprise an antibody.
5 . The method as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1.
6 . The method as recited in claim 1 wherein said composition does not comprise a lung membrane dipeptidase-binding molecule.
7 . The method as recited in claim 1 wherein said targeting moiety does not target a lung membrane dipeptidase.
8 . The method as recited in claim 1 wherein said targeting moiety targets a damage-correlated moiety.
9 . The method as recited in claim 8 wherein said damage-correlated moiety comprises a cell surface marker.
10 . The method as recited in claim 8 wherein said damage-correlated moiety comprises an ECM component.
11 . The method as recited in claim 1 wherein said targeting moiety targets elastase.
12 . The method as recited in claim 1 wherein said targeting moiety targets neutrophil elastase.
13 . The method as recited in claim 1 wherein said targeting moiety comprises a protease inhibitor moiety.
14 . The method as recited in claim 1 wherein said targeting moiety comprises an alpha-1 antitrypsin moiety.
15 . The method as recited in claim 14 wherein said alpha-1 antitrypsin moiety is a recombinant alpha-1 antitrypsin moiety.
16 . The method as recited in claim 1 wherein said targeting moiety comprises an elafin moiety.
17 . The method as recited in claim 16 wherein elafin moiety is a recombinant elafin moiety.
18 . The method as recited in claim 1 wherein said targeting moiety comprises a serpin moiety.
19 . The method as recited in claim 18 wherein said serpin moiety is a recombinant serpin moiety.
20 . The method as recited in claim 18 wherein said serpin moiety is a secretory leukoprotease inhibitor (SLP1) moiety.
21 . The method as recited in claim 20 wherein said secretory leukoprotease inhibitor (SLP1) moiety is a recombinant secretory leukoprotease inhibitor (SLP1) moiety.
22 . The method as recited in claim 1 wherein said targeting moiety targets at least one matrix metalloproteinase selected from MMP-1, MMP-2, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, and MMP-9.
23 . The method as recited in claim 22 wherein said composition does not comprise a hyaluronic acid or a salt thereof.
24 . The method as recited in claim 1 wherein said targeting moiety targets desmosine and/or isodesmosine.
25 . The method as recited in claim 1 wherein said targeting moiety targets CD8 and/or CD4.
26 . The method as recited in claim 1 wherein said targeting moiety targets a smoke-related moiety.
27 . The method as recited in claim 1 wherein said imaging moiety comprises a contrasting agent.
28 . The method as recited in claim 27 wherein said contrasting agent is non-ionic.
29 . The method as recited in claim 27 wherein said contrasting agent is ionic.
30 . The method as recited in claim 1 wherein said imaging moiety comprises at least one metal compound selected from a tantalum compound and a barium compound.
31 . The method as recited in claim 1 wherein said imaging moiety comprises iodine.
32 . The method as recited in claim 1 wherein said imaging moiety comprises at least one organic iodo acid selected from an iodo carboxylic acid, a triiodophenol, an iodoform, and a tetraiodoethylene.
33 . The method as recited in claim 1 wherein said imaging moiety comprises a non-radioactive moiety.
34 . The method as recited in claim 1 wherein said imaging moiety comprises a proton-emitting moiety.
35 . The method as recited in claim 1 wherein said imaging moiety comprises a radiopaque moiety and/or a radioactive moiety.
36 . The method as recited in claim 1 wherein said imaging moiety comprises a magnetic moiety.
37 . The method as recited in claim 1 wherein said imaging moiety comprises a radiopharmaceutical.
38 . The method as recited in claim 1 wherein said imaging moiety comprises an In-111 moiety.
39 . The method as recited in claim 1 wherein said imaging moiety comprises a Tc-99m moiety.
40 . The method as recited in claim 1 wherein said imaging moiety comprises an Xe-133 moiety.
41 . The method as recited in claim 1 wherein said composition is less than 10 microns.
42 . The method as recited in claim 1 wherein said composition is less than 5 microns.
43 . The method as recited in claim 1 wherein said composition is less than 1 micron.
44 . The method as recited in claim 1 wherein said administering is carried out via inhalation.
45 . The method as recited in claim 44 wherein said inhalation is carried out via the mouth.
46 . The method as recited in claim 1 wherein said administering is carried out via trans-thoracic administration.
47 . The method as recited in claim 1 wherein said administering is carried out via intravenous administration.
48 . The method as recited in claim 1 wherein said imaging of said damaged lung tissue is carried out via a radiological technique.
49 . The method as recited in claim 48 wherein said radiological technique is at least one selected from an X-ray, a CT scan, a PET scan, a nuclear scan, a SPECT, and a scintigraphy.
50 . The method as recited in claim 1 wherein said composition further comprises a coupled cross-linkable moiety and/or another coupled targeting moiety.
51 . The method as recited in claim 50 , further comprising cross-linking and/or sealing said damaged lung tissue.
52 . The method as recited in claim 1 , further comprising administering a washing moiety.
53 . A method of diagnosing a pulmonary condition comprising:
administering to a subject a composition comprising an imaging moiety and a targeting moiety wherein said moieties are coupled and wherein said targeting moiety targets damaged lung tissue; and
imaging said damaged lung tissue.
54 . The method as recited in claim 53 wherein said lung tissue comprises epithelial lining fluid.
55 . The method as recited in claim 53 wherein said pulmonary condition is emphysema.
56 . The method as recited in claim 53 wherein said pulmonary condition is COPD.